{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:16:12Z","timestamp":1785352572835,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016126","name":"Beijing Hospitals Authority","doi-asserted-by":"publisher","award":["ZLRK202327"],"award-info":[{"award-number":["ZLRK202327"]}],"id":[{"id":"10.13039\/100016126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91959130"],"award-info":[{"award-number":["91959130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403443"],"award-info":[{"award-number":["82403443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-HH202101-0068"],"award-info":[{"award-number":["Y-HH202101-0068"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-tongshu2021\/ms-0040"],"award-info":[{"award-number":["Y-tongshu2021\/ms-0040"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xcrm.2025.102296","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T16:33:40Z","timestamp":1755275620000},"page":"102296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Toripalimab, bevacizumab, and irinotecan in dMMR\/MSI locally advanced colorectal cancer: First-stage results from a phase 1b\/2 trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Zhenghang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mifen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102296_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2025.102296_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib3","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2022.40.16_suppl.3510","article-title":"Nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients (pts) with microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142","volume":"40","author":"Overman","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","article-title":"Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib6","doi-asserted-by":"crossref","first-page":"S1390","DOI":"10.1016\/j.annonc.2022.08.019","article-title":"LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial","volume":"33","author":"Taieb","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib7","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102296_bib8","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1200\/JCO.2010.33.0092","article-title":"Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803","volume":"29","author":"Bertagnolli","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102296_bib10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102296_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2025.102296_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2022.7060","article-title":"Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer","volume":"21","author":"Xiao","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.xcrm.2025.102296_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2009.24.0952","article-title":"Revised TN categorization for colon cancer based on national survival outcomes data","volume":"28","author":"Gunderson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial","volume":"41","author":"Morton","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15180","article-title":"A molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"Cortes-Ciriano","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102296_bib16","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102296_bib17","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1078-0432.CCR-19-3728","article-title":"Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy","volume":"26","author":"Cercek","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102296_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2025.102296_bib19","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102296_bib20","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s00262-023-03480-w","article-title":"Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer","volume":"72","author":"Veen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102296_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12943-021-01317-7","article-title":"Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades","volume":"20","author":"Li","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2025.102296_bib23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102296_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00262-020-02676-8","article-title":"Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer","volume":"70","author":"Min","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102296_bib25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2023.41.4_suppl.358","article-title":"INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC)","volume":"41","author":"Pietrantonio","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.20.01600","article-title":"Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials","volume":"39","author":"Cohen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(24)00203-1","article-title":"Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study","volume":"25","author":"Yu","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.6004\/jnccn.2022.7071","article-title":"Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors","volume":"21","author":"Xie","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.xcrm.2025.102296_bib29","article-title":"Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR\/MSI rectangleH Locally Advanced Colorectal Cancer: A Single-Center Real-World Study","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102296_bib30","first-page":"85","article-title":"Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer","volume":"22","author":"Pei","year":"2023","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.xcrm.2025.102296_bib31","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102296_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004703","article-title":"Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR\/MSI-H gastrointestinal cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102296_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002797","article-title":"Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors","volume":"9","author":"Hwang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102296_bib34","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1158\/1078-0432.CCR-21-0401","article-title":"A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H\/dMMR Gastrointestinal Tumors","volume":"27","author":"Chida","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102296_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004001","article-title":"Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers","volume":"10","author":"Fuca","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102296_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andre","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102296_bib37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/oncolo\/oyad082","article-title":"BRAF V600E\/RAS Mutations and Lynch Syndrome in Patients With MSI-H\/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors","volume":"28","author":"Colle","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2025.102296_bib38","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s10147-024-02527-x","article-title":"Clinicopathological characteristics of Lynch-like syndrome","volume":"29","author":"Nakamori","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205158","article-title":"The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102296_bib40","article-title":"PD-1\/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1\/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study","volume":"7","author":"Chen","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib41","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO.2024.42.16_suppl.3505","article-title":"Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high\/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study","volume":"42","author":"Xu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib42","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1245\/s10434-024-16755-y","article-title":"Neoadjuvant Immunotherapy Followed by Surgery Compared with Upfront Surgery Alone in Operable Colon Cancer with Deficient Mismatch Repair: Modeling Oncological Outcomes and Numbers Needed to Treat","volume":"32","author":"Kanani","year":"2025","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib43","doi-asserted-by":"crossref","first-page":"S1217","DOI":"10.1016\/j.annonc.2024.08.2263","article-title":"LBA24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2","volume":"35","author":"Chalabi","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib44","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.annonc.2024.08.611","article-title":"542P Long-term outcomes of neoadjuvant toripalimab with or without celecoxib in patients with dMMR\/MSI-H locally advanced colorectal cancer: 3-month treatment cohort of the randomized phase II PICC trial","volume":"35","author":"Hu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102296_bib45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00262-024-03764-9","article-title":"Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR\/MSI-H colorectal and gastric cancers","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102296_bib46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1177\/1740774513497539","article-title":"Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials","volume":"10","author":"Berry","year":"2013","journal-title":"Clin. Trials"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:25:19Z","timestamp":1772918719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125003696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666379125003696"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102296","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toripalimab, bevacizumab, and irinotecan in dMMR\/MSI locally advanced colorectal cancer: First-stage results from a phase 1b\/2 trial","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102296"}}